Studies on the Transfer of Natural E. Coli Antibody Production in Rats

Author(s):  
K. Merétey ◽  
E. Elekes ◽  
V. Várterész ◽  
L. Kocsár
Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 4337-4337
Author(s):  
Yves Bertrand ◽  
Marie Pierre Goutagny ◽  
Anne Lise Poulat ◽  
Sandrine Girard ◽  
Cecile Acquaviva ◽  
...  

Abstract Randomised trials in pediatric ALL show that multiple doses of E Coli Asparaginase (ASP) are associated with better outcome. In the EORTC 58951 protocol, all the patients except those with high risk features (HR or VHR) had 8 IV doses of ASP during induction Ia and were randomized during induction Ib to receive or not ASP (8 IV doses vs 0) and protocol II (8 IV doses vs 4), respectively long arm and short arm. The aim of this study was to report on safety, asparagine (ASN) depletion and antibody production in 28 consecutive patients with newly diagnosed previously untreated ALL. Methods. Twenty-eight patients included in the EORTC 58951 protocol were analyzed: one had very low risk features, 22 were average risk patients and 6 had HR features. Thirteen patients were randomized in the short ASP arm and 9 in the long ASP arm. ASN levels were assessed on days 35 of Ia, 27of Ib and 22 of IIa. The amino acid assays employed the HPLC method. Serum samples were taken for antibody titers against ASP analyzed by ELISA on days 12 and 35 of Ia, 17 and 27 of Ib (long arm only) and 8 and 22 of IIa, and before the start of maintenance therapy. Results. Twenty-eight patients aged 1year 3 months to 14 years 6 months (median 6 years) with newly diagnosed ALL (precursor B-cell: 25 ; T-cell: 3) were assessable. All patients achieved CR after induction phase Ia. Four patients had allogeneic bone marrow transplantation in first CR because of VHR features. Two other patients with HR features had intensified chemotherapy. Preliminary data showed that ASN depletion was obtained in all patients at the end of phase Ia, in all the patients “long arm” at the end of Ib and in one patient ” short arm” at the end of Ib All patients had depletion of ASN after protocol IIa We observed very few severe clinical allergic reactions in this series of patients (10%). Two patients were switched to Erwinia asparaginase because of clinical hypersensitivity. Investigation on correlation between the antibody production against ASP, clinical allergic reaction and depletion of ASN are in progress. Conclusions. Multiple doses of ASP given intravenously were well tolerated in this series of 28 consecutive patients with previously untreated ALL. Preliminary results reveal that the rate of antibodies production was low and depletion of ASN was obtained in near all the patients. Some patients presented with clinical allergic reactions but had low levels of ASN and no appearance of anti ASP antibodies. Other had antibodies without clinical allergy and with depletion of ASN.


1996 ◽  
Vol 190 (1) ◽  
pp. 143-145 ◽  
Author(s):  
Giovanni Covini ◽  
Edward K.L. Chan ◽  
Massimo Colombo ◽  
E.M. Tan

2012 ◽  
Vol 518-523 ◽  
pp. 305-308 ◽  
Author(s):  
Hui Yao ◽  
Xiao Hui Zhang ◽  
Hong Zong Yin

This work describes an approach for the development of two bacteria biosensors based on surface plasmon resonance (SPR) technique. The first biosensor was based on functionalized gold substrate and the second one on immobilized silver nanoparticles. For the first biosensor, the gold substrate was functionalized with acid–thiol using the self-assembled monolayer technique, while the second one was functionalized with silver nanoparticles immobilized on modified gold substrate. A polyclonal anti-Escherichia coli antibody was immobilized for specific (E. coli) bacteria detection. Detection limit with a good reproducibility of 104 and 103 cfu•mL−1 of E. coli bacteria has been obtained for the first biosensor and for the second one respectively.


1996 ◽  
Vol 39 ◽  
pp. 173-173
Author(s):  
A Hoberman ◽  
E R Wald ◽  
E A Reynolds ◽  
M Charron ◽  
J A Roberts

Author(s):  
Seiji SASAKI ◽  
Masao IIYAMA ◽  
Jun-ichi ISHIKAWA ◽  
Hideaki ENDO ◽  
Yoshinobu KOUYAMA
Keyword(s):  

1978 ◽  
Vol 147 (4) ◽  
pp. 1007-1017 ◽  
Author(s):  
C E Davis ◽  
E J Ziegler ◽  
K F Arnold

Antibodies to Escherichia coli J5, a uridine 5'-diphosphate-galactose epimerase-less mutant of E. coli 0111, neutralized meningococcal endotoxemia from all three major capsular serogroups. We chose the dermal necrosis of the local Shwartzman phenomenon and the renal cortical necrosis of the general Shwartzman phenomenon as assays because these are the hallmarks of meningococcemia, and because meningococcal lipopolysaccharide (LPS) is a uniquely potent cause of dermal purpura and necrosis. Meningococcal antisera raised against LPS from MGC A, B, and C also provided good protection against endotoxemia from the homologous capsular groups, but it was inconsistent against the heterologous serogroups. The superiority of J5 antibodies (purified IgG as well as antiserum) is probably due to the fact that J5 LPS contains only the endotoxin core. Consequently, immunization with this mutant stimulates production of antibodies to core LPS without interference by the "0" antigenic determinants of the side chains. These observations indicate that the endotoxin core is the toxic moiety of meningococcal LPS, that the core LPS of meningococcus (MGC) is immunologically similar to enteric LPS, and that the antigenically variable "0" side chains of MGC LPS interfere with antibody production against the common core. They also suggest that antibodies prepared against this E. coli mutant could interrupt the devastating course of meningococcal endotoxemia in man, regardless of the capsular serogroup of the infecting strain.


BMJ ◽  
1973 ◽  
Vol 3 (5870) ◽  
pp. 14-18 ◽  
Author(s):  
H. J. Andersen ◽  
B. Jacobsson ◽  
H. Larsson ◽  
J. Winberg
Keyword(s):  
E Coli ◽  

Sign in / Sign up

Export Citation Format

Share Document